TransMedics Director Sells 4,142 Shares as Wall Street Maintains Buy Ratings: Is the Stock Still a Buy?
Director Edward Basile executed an exercise of 4,142 options with immediate sale of all resulting shares in TransMedics Group (NASDAQ:TMDX) on October 29, 2025, as disclosed in the SEC Form 4...
Nasdaq News: Markets·4d ago